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Summary
Hypogonadotropichypogonadismischaracterisedbyinsufficientsecretionofpituitarygonadotropinsresultingindelayed
puberty, anovulation and azoospermia. When hypogonadotropic hypogonadism occurs in the absence of structural or 
functionallesionsofthehypothalamicorpituitarygland,thehypogonadismisdefinedasidiopathichypogonadotropic
hypogonadism (IHH). This is a rare genetic disorder caused by a defect in the secretion of gonadotropin releasing 
hormone (GNRH) by the hypothalamus or a defect in the action of GNRH on the pituitary gland. Up to 50% of IHH cases 
haveidentifiablepathogenicvariantsinthecurrentlyknowngenes.PathogenicvariantsintheGNRHR gene encoding the 
GNRH receptor are a relatively common cause of normosmic IHH, but reports of pathogenic variants in GNRH1 encoding 
GNRH are exceedingly rare. We present a case of two siblings born to consanguineous parents who were found to have 
normosmic idiopathic hypogonadotropic hypogonadism due to homozygosity of a novel loss-of function variant in GNRH1. 
Case 1 is a male who presented at the age of 17 years with delayed puberty and under-virilised genitalia. Case 2 is a 
female who presented at the age of 16 years with delayed puberty and primary amenorrhea.
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Learning points:
 • IHHisageneticallyheterogeneousdisorderwhichcanbecausedbypathogenicvariantsaffectingproteins
involved in the pulsatile gonadotropin-releasing hormone release, action, or both.
 • Currently known genetic defects account for up to 50% of all IHH cases.
 • GNRH1 pathogenic variants are a rare cause of normosmic IHH.
 • IHH is associated with a wide spectrum of clinical manifestations.
 • IHHcanbechallengingtodiagnose,particularlywhenattemptingtodifferentiateitfromconstitutionaldelayof
puberty.
 • Early diagnosis and gonadotrophin therapy can prevent negative physical sequelae and mitigate psychological 
distresswiththerestorationofpubertyandfertilityinaffectedindividuals.
S V Sagi and others Idiopathic hypogonadotropic 
hypogonadism DOI: 10.1530/EDM-19-0145
https://edm.bioscientifica.com/ 2
ID: 19-0145; March 2020
Background
Hypogonadotropic hypogonadism is characterised by 
low levels of testosterone or oestradiol in the presence of 
impaired or defective secretion of luteinizing (LH) and 
follicle stimulating hormone (FSH) from the pituitary 
gland. In the absence of any anatomical or functional 
lesions of the pituitary or hypothalamic gland, the 
hypogonadotropic hypogonadism is referred to as 
idiopathic hypogonadotropic hypogonadism (IHH).
The defect in the synthesis and secretion of pituitary 
hormones is intricately linked to the release and action 
of gonadotropin releasing hormone (GNRH) from the 
hypothalamus. GNRH is the central regulator in reproductive 
function and sexual development. The secretion of GNRH 
is pulsatile in nature, being suppressed in childhood and 
activated with progression into and through puberty. The key 
factors responsible for successful pulse-generator activation 
of sexual development are the frequency and amplitude of 
the GNRH pulses. The failure to activate pulsatile secretion 
leads to hypogonadotropic hypogonadism (1). The clinical 
manifestations can range from incomplete or failure to go 
through puberty, cryptorchidism, micropenis, and infertility 
in males to primary amenorrhea, failure to go through 
puberty, growth retardation, and infertility in females. 
Osteoporosis can result from untreated hypogonadism, 
and bimanual synkinesis (mirror movements) has also been 
reported in some individuals. Syndromic IHH, such as those 
caused by pathogenic variants in the FGFR1 gene, can be 
associated with dysmorphic and other clinical features such 
as hypodontia, cleft lip and palate, and digital anomalies 
such as syndactyly and ectrodactyly are other clinical 
manifestations.
Idiopathic hypogonadotropic hypogonadism with 
normal sense of smell (normosmic IHH) or with hypo-
osmia or anosmia (Kallman syndrome) is a complex and 
rare disorder characterised by insufficient GNRH neuronal 
action on an otherwise normal hypothalamo-pituitary-
gonadal axis. This could be due to defective development 
or migration of GNRH neurones, impaired secretion of 
GNRH from neurons, disrupted interaction between the 
GNRH ligand and its receptor, or impaired secretion of 
LH and FSH (2, 3). To date, pathogenic variants in around 
50 genes have been reported to cause IHH which account 
for up to 50% of IHH cases, suggesting that further genes 
remain to be discovered (4). IHH has an incidence of 1–10 
in 100,000 live births with a variable mode of inheritance 
and five-fold male predominance (2).
Kallman syndrome is genetically heterogeneous: the 
ANOS1 gene has been implicated in 10–20% of cases. 
Normosomic IHH is also genetically heterogeneous, of 
which pathogenic variants in GNRHR and TACR3 are the 
most frequent cause (in two-thirds of variants detected) 
(4). We report a rare case of normosmic IHH in two siblings 
from a consanguineous family caused by homozygosity 
for a novel frameshift likely pathogenic variant in the 
GNRH1 gene.
Case presentation
Case 1
Medical history and demographics
A 17-year-old male presented with a history of delayed 
puberty. He was born to healthy second-cousin 
parents of Pakistani origin from a family with multiple 
consanguineous relationships. Two paternal aunts were 
said to be infertile. He did not report any headache or visual 
disturbances. His sense of smell was intact. He was born 
3 months prematurely by caesarean section. The patient 
had normal development and growth with no learning 
difficulties. He was not allergic to any medications. On 
examination, he was found to be overweight with a 
weight of 86.4 kg (BMI of 27.3) and height of 178 cm 
(50th percentile). Mid-parental target height (based on 
maternal height of 162 cm and paternal height of 185 
cm) was 172–189 cm. His right testis was small and his 
left testis was not palpable. He had hypoplastic scrotum, 
micro-penis, and bilateral gynaecomastia.
Investigation
The results of the baseline blood tests with normal reference 
levels are shown in Table 1. Results demonstrated low 
testosterone and oestradiol levels with inappropriately low 
gonadotrophin levels consistent with hypogonadotropic 
hypogonadism. Gonadotropin releasing hormone 
stimulation test illustrated low testosterone levels and no 
elevation of basal gonadotropins levels. Ultrasound of the 
testes revealed small avascular testes (right testis measuring 
11.2 mm x 6.5 mm x 10.8 mm; left testis measuring 13.2 
mm x 5.7 mm x 6.8 mm). The corresponding testicular 
volumes were 0.56 mL and 0.36 mL, respectively. An 
MRI pituitary contrast scan showed a pituitary gland of 
normal size and appearance. A bone density scan revealed 
a low for age value in the lumbar spine (z-score of −2.5 
s.d., 0.766 g/cm2) and neck of femur (z-score of −1.7 s.d., 
0.795 g/cm2). Subsequent chromosomal analysis revealed 
46 XY karyotype.
Next Generation Sequencing (NGS) of the coding region 
(+/−5 bp) of the following genes (reference sequences) 
using the Illumina TruSight One sequencing panel was 
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arranged: CHD7 (NM_017780.3); FGF8 (NM_033163.3); 
FGFR1 (NM_001174067.1); GNRH1 (NM_000825.3); 
GNRHR (NM_000406.2); KAL1 (NM_000216.2); KISS1 
(NM_002256.3); KISS1R (NM_032551.4); PROK2 
(NM_001126128.1); PROKR2 (NM_144773.2); TAC3 
(NM_013251.3); and TACR3 (NM_001059.2). Additionally, 
97.73% of the target sequence within this panel was 
sequenced to a depth of 20 fold or more, with analytical 
sensitivity of 98.3%–100% (95% CI). An apparent 
homozygous likely pathogenic variant in the GNRH1 
gene was detected and confirmed via Sanger sequencing: 
(NM_000825.3 (GNRH1-v001):c.119_122dupGAGA 
p.(Asp37GlufsTer8)). This is demonstrated in Fig. 1.
This GNRH1 variant is considered extremely rare as it is 
absent from known disease database (ClinVar and Human 
Gene Mutation Database (HGMD)) and the population 
frequency database (Genome Aggregation Database 
(GnomAD)). The c.119_122dup GNRH1 variant leads to 
the insertion of a GAGA tetra-nucleotide, which alters 
the reading frame of the protein and leads to a premature 
STOP codon in the GNRH1 gene. This is predicted to 
cause loss of normal protein function either through 
protein truncation or nonsense-mediated mRNA decay. 
Other small deletions and insertions, which are similarly 
predicted to shift the reading frame and result in a 
premature STOP codon, have been reported as pathogenic 
in association with hypogonadotropic hypogonadism.
Subsequently, the parents of these siblings were 
tested for the familial likely pathogenic c.119_122dup 
GNRH1 variant and each shown to be heterozygous. This 
confirms bi-parental inheritance of the likely pathogenic 
c.119_122dup p.(Asp41GlufsTer8) GNRH1 variant in the 
affected siblings and is consistent with a diagnosis of 
autosomal recessive IHH in this family.
Treatment
The patient was started on an i.m. injection of 
testosterone (Sustanon 50 mg) once every 4 weeks with a 
gradual increase in dose. He was also started on calcium 
and vitamin D supplements and advised to maintain a 
healthy lifestyle with regular exercise.
Outcome and Follow-up
The patient’s testosterone levels improved with hormone 
replacement therapy. He has shown progression with 
sexual development and is being regularly followed up in 
the Endocrine clinic. The patient has received counselling 
concerning infertility.
Table 1 Baseline blood results for both patients with 
laboratory reference ranges.
Endocrine test Reference range
Case 1  
(M)
Case 2 
(F)
Testosterone,  
nmol/L
10–38 nmol/L 0.3 –
Oestradiol, pmol/L 100–750 pmol/L – <37
Prolactin, mU/L <500 mU/L 144 217
LH, U/L (basal) 1–9 U/L <1 <1
FSH , U/L (basal) 1–14 U/L <1 <1
Stimulated LH,  
mU/L*
 20min M: 13–58; F: 15–42 <1 <1
 60min M: 11–48; F: 12–35 <1 <1
Stimulated FSH, 
mU/L*
 20min M: 1–7; F: 1–11 <1 <1
 60min M: 1–5; F: 1–25 1 1
Free thyroxine, 
pmol/L
12–22 pmol/L 13.1 13.5
TSH, mU/L 0.3–4.2 mU/L  2.42 1.30
Sodium, mmol/L 133–146 mmol/L 140 140
Potassium, mmol/L 3.5–5.3 mmol/L 4.1 4.3
Haemoglobin, g/L M: 130–180;  
F:115–165 
146 132
Haematocrit M: 0.400–0.530;  
F: 0.360–0.460 
0.424 0.387
*After an i.v. injection of gonadotrophin-releasing hormone (Gonadorelin 
100 μg) as part of the GNRH stimulation test
F, female; FSH, follicle stimulating hormone; LH, luteinizing hormone; M, 
male; TSH, thyroid stimulating hormone.
Figure 1
Chromatogram of the Sanger sequencing. (A) 
Patients’ chromatogram showing the duplicated 
tetra-nucleotide base (arrow) and glutamate (Glu) 
replacing the wild-type aspartate (Asp) at position 
37 and the STOP 8 amino acids downstream. (B) 
Normal reference chromatogram.
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Case 2
Medical history and demographics
A 16-year-old female (sibling to case 1) presented with a 
history of delayed puberty and primary amenorrhoea. She 
had no headaches or visual disturbance. She was born at 
term by normal vaginal delivery. She had a cleft palate 
at birth which was repaired with no adverse effect on 
speech and feeding. On examination, she had a weight 
of 53.5 kg (BMI of 20.9) and height of 160 cm (30th 
percentile). Mid-parental target height was 159–176 cm. 
She had hyperpigmented linear rashes over her arms and 
chest (thought to be a lichenoid reaction). She had chest 
adiposity, but breast buds were difficult to palpate. Her 
axillary hair was Tanner stage 1 and pubic hair Tanner 
stage 2. She reported a normal sense of smell.
Investigation
The results of the baseline blood tests with normal reference 
levels are shown in Table 1. Results demonstrated low 
estradiol levels with inappropriately low gonadotropin 
levels consistent with hypogonadotropic hypogonadism. 
Gonadotropin releasing hormone stimulation test 
produced no elevation of basal gonadotropins. Ultrasound 
of the pelvis demonstrated a small infantile uterus 
measuring 3.5 cm x 1.2 cm x 1.9 cm; both ovaries were not 
demonstrated due to bowel shadowing, and endometrial 
lining was not visible. An MRI pituitary contrast scan 
showed a pituitary gland of normal size and appearance. 
A bone density scan revealed levels in the lower end of 
the normal range for age in the lumbar spine (z-score 
of −1.2 s.d., 0.842 g/cm2) and neck of femur (z-score of 
−1.5 s.d., 0.70 g/cm2). Subsequent chromosomal analysis 
revealed a 46 XX karyotype. She was tested for the 
familial GNRH1 variant detected in her brother and was 
confirmed as being homozygous for the same variant 
(NM_000825.3 (GNRH1-v001):c.119_122dupGAGA 
p.(Asp37GlufsTer8)).
Treatment
The patient was started on a pubertal induction regimen 
with ethinyl estradiol 2 μg daily. The dose was increased 
by 2 μg every six months. She progressed through puberty 
well and had break-through vaginal bleeding on a dose 
of 12 μg daily. At this stage, her treatment was changed 
to the combined oral contraceptive pill (Loestrin 20) to 
induce regular withdrawal bleeding.
Outcome and follow-up
The patient had progression in terms of puberty (breast: 
stage 2–3, pubic hair: stage 2–3, axillary hair: stage 1). 
She was counselled about fertility and is being regularly 
followed up in the Gynaecological Endocrine clinic.
Discussion
Idiopathic hypogonadotropic hypogonadism (IHH) is a 
complex genetic disorder that is characterised by genetic 
heterogeneity, variable expression, penetrance, and modes 
of inheritance. Classically, IHH has been categorized 
into two distinct clinical entities: Kallmann syndrome 
and normosmic IHH. IHH can also be syndromic. More 
recently, it has been noted that the IHH phenotype is 
variable, partially due to oligo-genic mode of inheritance 
and gene–environment interactions (1, 2).
The GNRH1 (OMIM number 614841) gene is located 
on the short arm of chromosome 8 at position 21.2. 
It encodes a preproprotein (progonadoliberin-1, pro-
GNRH1), which after proteolytic splicing releases the 
active decapeptide GNRH1 and the GNRH-associated 
peptide. The decapeptide GNRH1 triggers the release of 
luteinizing hormone and follicle stimulating hormone 
from the pituitary gland. The GNRH1 gene is expressed 
in a select population of hypothalamic neurones and a 
defect results in hypogonadotropic hypogonadism.
Pathogenic variants have been reported in many 
different genes in patients with IHH, but those in one 
of the most obvious candidate gene, GNRH1, have rarely 
been reported. In a study involving 310 patients with 
normosmic idiopathic hypogonadotropic hypogonadism 
(normosmic IHH), five patients were identified with 
rare bi-allelic variants in GNRH1 consisting of missense, 
nonsense, and frameshift variants (5). In another cohort 
of 130 unrelated patients with IHH, a novel homozygous 
splice site variant was detected in GNRH1 in a single 
case (6). Another case of normosmic IHH due to a single 
nucleotide insertion resulting in a frameshift variant in 
the GNRH1 gene was identified in a brother and sister of 
non-consanguineous parents of Romanian origin (7). The 
clinical consequence of these inactivating variants in the 
GNRH1 gene is an absence of the intact GNRH1 protein 
and resultant failure to stimulate gonadotropin release 
from the pituitary gland.
The diagnosis of IHH and differentiating it from 
constitutional delay of puberty can be very challenging. 
A timely diagnosis and treatment to induce puberty can 
be beneficial for sexual, bone, and metabolic health and 
might help minimize some of the psychological effects 
of this rare condition (8). If patients wish to conceive, 
ovulation or spermatogenesis can be induced using 
gonadotrophins.
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We report two siblings with non-syndromic IHH 
born of a consanguineous union who were found to be 
homozygous for a novel likely pathogenic frameshift 
variant in the GNRH1 gene resulting in low gonadotropin 
levels. Parental testing has confirmed bi-parental 
inheritance. It is uncertain whether the cleft palate in the 
female patient is related to IHH, as cleft palate in itself 
is a relatively common congenital anomaly (affecting 1 
in 2500 births) and is not a reported feature in previous 
cases of GNRH1-related IHH. The autosomal recessive 
inheritance confirms a recurrence risk of one in four 
for each future pregnancy for the parents, who are still 
of reproductive age, and an increased risk to any future 
consanguineous relationships within the family.
In conclusion, we have presented a case of normosmic 
IHH in two siblings from a consanguineous family due 
to a novel frameshift variant in the GNRH1 gene. We 
hope that this case report not only adds to the existing 
literature but also contributes to gaining insight into a 
complex genetic condition.
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